JawaPos.com–The Food and Drug Administration (BPOM) hopes that the Red and White vaccine has been registered with the World Health Organization or WHO. So that in the future it will not only become an alternative choice for the country, but also become an export product.
According to the Head of the Food and Drug Supervisory Agency (BPOM) Penny Kusumastuti Lukito, if the vaccine can be registered with WHO and exported, it is not impossible to change its name to become more universal.
“Maybe later with that name we ask the President (Joko Widodo) with a universal name if it is really exported,” said Penny Kusumastuti Lukito at the Kick Off event > Red and White Vaccine Clinical Trial Phase 3 at Campus A, Universitas Airlangga Surabaya, Monday (27/6).
Penny also hopes that the phase three Red and White vaccine clinical trial will run smoothly and the results can be obtained soon. The success of developing the Unair Merah Putih vaccine is a source of pride for all elements of the nation. Because, this is the nation’s first vaccine.
“Really starting from scratch at home. So from the seeds of the vaccine, the virus from Indonesia, from our patients in Indonesia. Very proud,” said Penny.
Meanwhile, Director of Pharmaceutical Production and Distribution of the Ministry of Health (Kemenkes) Agusdini Banun Saptaningsih stated that the development of the Unair Merah Putih vaccine was a major step in Indonesia’s efforts to achieve independence in the field of vaccine production. The Covid-19 pandemic has awakened policy makers to strengthen health system defenses.
“We will also carry out transformations in the health sector, one of which is for the resilience of the health system through pharmaceutical resilience,” said Agusdini Banun Saptaningsih.
Regarding the designation of Unair’s Red and White vaccine, Agusdini said, it is possible that it could be used for booster and children’s vaccines.
“We still can’t confirm the age range of the children targeted for the UNAIR Merah Putih vaccine because we still have to do further research,” said Agusdini Banun Saptaningsih.
Currently, Unair Surabaya has officially started clinical trials of the third phase of the Red and White vaccine after obtaining permission from BPOM. In the third phase of clinical trials there were 4,005 subjects who were prepared to participate in the study and were divided into three groups. That is one control group and two treatment groups.